The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Enfusion Inc’s stock clocked out at $10.96, up 0.37% from its previous closing price of $10.92. In other words, the price has increased by $0.37 from its previous closing price. On the day, 2.51 million shares were traded. ENFN stock price reached its highest trading level at $10.99 during the session, while it also had its lowest trading level at $10.915.
Ratios:
To gain a deeper understanding of ENFN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 29.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 70.96. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 3.62. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.22.
On February 28, 2024, Goldman Downgraded its rating to Sell which previously was Neutral and also lowered its target price recommendation from $9 to $8.
JP Morgan Downgraded its Neutral to Underweight on January 30, 2024, whereas the target price for the stock was revised from $11 to $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 13 ’25 when Somers Deirdre sold 1,637 shares for $10.53 per share. The transaction valued at 17,238 led to the insider holds 41,675 shares of the business.
Somers Deirdre bought 1,637 shares of ENFN for $17,241 on Jan 13 ’25. On Jan 07 ’25, another insider, Movchan Oleg, who serves as the Chief Executive Officer of the company, sold 2,771 shares for $10.13 each. As a result, the insider received 28,070 and left with 526,702 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENFN now has a Market Capitalization of 1038673792 and an Enterprise Value of 1033400896. As of this moment, Enfusion’s Price-to-Earnings (P/E) ratio for their current fiscal year is 418.32, and their Forward P/E ratio for the next fiscal year is 38.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.24 while its Price-to-Book (P/B) ratio in mrq is 14.62. Its current Enterprise Value per Revenue stands at 5.295 whereas that against EBITDA is 55.778.
Stock Price History:
The Beta on a monthly basis for ENFN is 0.95, which has changed by 0.23809528 over the last 52 weeks, in comparison to a change of 0.22677135 over the same period for the S&P500. Over the past 52 weeks, ENFN has reached a high of $11.38, while it has fallen to a 52-week low of $7.52. The 50-Day Moving Average of the stock is 7.95%, while the 200-Day Moving Average is calculated to be 18.99%.
Shares Statistics:
It appears that ENFN traded 604.17K shares on average per day over the past three months and 1297650 shares per day over the past ten days. A total of 93.26M shares are outstanding, with a floating share count of 48.78M. Insiders hold about 48.31% of the company’s shares, while institutions hold 59.45% stake in the company. Shares short for ENFN as of 1735603200 were 556497 with a Short Ratio of 0.92, compared to 1732838400 on 820410. Therefore, it implies a Short% of Shares Outstanding of 556497 and a Short% of Float of 1.2200001.
